ArticlePhysics and imaging in radiation oncology2026
Deep learning-based generation of direct stopping power ratio maps for MR-only proton therapy of primary brain tumor patients.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: A magnetic resonance-only proton therapy (MRoPT) workflow requires synthetic computed tomography (CT) to derive the stopping power ratio (SPR) for treatment planning. Here, we introduce three U-Net models to predict synthetic SPR (sSPR) maps from magnetic resonance imaging (MRI) scans of primary brain tumor patients. Materials and methods: SPR maps and heterogenous MRI data were collected from 140 patients. Three 2D-U-Net models were independently developed with axial, coronal, and sagittal MRI scan slices, the combination of which resulted in 2.5D sSPR.To evaluate the sSPR and associated dose maps, the mean absolute error (MAE), dose volume histogram-parameter differences, e.g. D2% and D98% of the clinical target volume (CTV), and the mean and maximum dose (Dmean and Dmax, respectively) for organs at risk (OAR; brainstem, optic chiasm, optic nerves, lacrimal glands and whole brain) were computed. Finally, gamma and range shifts analyses were performed. Results: The head cohort mean MAE was 0.062 ± 0.009 for the 2.5D sSPR. For the CTV, D2% and D98% differences ranged from -0.60% to 0.75%. Regarding the OAR, the Dmean and Dmax differences, corrected for relative biological effectiveness, were within ±2.70Gy (RBE). The mean pass rate for the local gamma criterion of 2%/2 mm with 10% dose threshold was 76.19 ± 4.67%. Averages of absolute range shifts ranged from 0.50 mm to 1.79 mm. Conclusions: Generated sSPR showed minor discrepancies from SPR. This study is a step closer to an MRoPT workflow for brain tumor patients, albeit the residual errors full impact needs to be more investigated in future work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.